Point-Of-Care Lateral Flow Reader Delivers High-Sensitivity Measurements In 10 Seconds
|
By LabMedica International staff writers Posted on 12 Aug 2024 |
|
A customizable point-of-care (POC) lateral flow reader combines advanced imaging technology and proprietary algorithms to deliver high-sensitivity measurements in just 10 seconds.
The miniDxR lateral flow reader designed by DCN Dx (Carlsbad, CA, USA) for POC testing offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features. It is customizable for diverse diagnostic applications, providing reliable and accurate results in diverse POC settings. The miniDxR utilizes advanced camera-based colorimetry and fluorescence for accurate and precise color and intensity detection, vital for the most sensitive POC diagnostics. It features a modular cartridge nest that can be customized to accommodate a wide variety of lateral flow assay cassettes, ensuring compatibility with a laboratory’s specific needs.
The miniDxR boasts a user-friendly interface with a vibrant color display and simple three-button control, enabling effortless operation even in fast-paced POC environments and while using gloves. Additional options are available to adapt screen size and button controls. It offers versatile “batch” and “single test” modes to accommodate diverse testing protocols, allowing labs to analyze pre-run assays or monitor lateral flow assays in real-time at the POC. Additionally, the miniDxR safeguards sensitive data with robust encryption and adheres to rigorous international standards, including FCC, IEC 61326, IEC 61010, IEC 60601, and IEC 62304, ensuring suitability for POC use.
The miniDxR offers a variety of customization options, from software workflows and data presentation to hardware modifications and branding. Every customized miniDxR unit comes with standard features such as pre-submission materials, product and software requirements, risk analysis, cybersecurity measures, verifications, and completion of the Design History File per FDA requirements. The miniDxR is designed to excel in both sophisticated clinical labs and challenging field environments.
"From its advanced capabilities to its range of customization options, our team designed this reader with the specific needs of point-of-care testing in mind," said Pat Vaughan, Ph.D., COO of DCN Dx.
Related Links:
DCN Dx
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read more
Hematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more
Immunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more
Microbiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Pathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more
Technology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more
Industry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more
